Canaccord Genuity Maintains Buy on Celldex Therapeutics, Raises Price Target to $68

Benzinga · 2d ago
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $68.